Indication: Bladder Cancer

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Adv Urothelial w/selected FGFR gene aberrations

Sub-indication: Metastatic or surgically unresectable urothelial Carcinoma with FGFR mutation

Line of Therapy: 2nd line, must have progressed on first line therapy and have one of the protocol defined FGFR translocations or mutations per central lab analysis.

Drug Study

Principal Investigator: Arash Rezazadeh, M.D.
Norton Cancer Institute

Sponsor: Janssen Research & Development

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.